vs
Side-by-side financial comparison of Nurix Therapeutics, Inc. (NRIX) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.
Xilio Therapeutics, Inc. is the larger business by last-quarter revenue ($13.7M vs $13.6M, roughly 1.0× Nurix Therapeutics, Inc.). Xilio Therapeutics, Inc. runs the higher net margin — 75.7% vs -576.1%, a 651.8% gap on every dollar of revenue. Xilio Therapeutics, Inc. produced more free cash flow last quarter ($-2.1M vs $-73.0M).
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel targeted protein degradation therapies for cancer, immune disorders and other serious unmet medical needs. Its core pipeline leverages proprietary E3 ubiquitin ligase modulation technology, with operations primarily based in the United States and collaborative partnerships with global pharmaceutical firms.
Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.
NRIX vs XLO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.6M | $13.7M |
| Net Profit | $-78.2M | $10.4M |
| Gross Margin | — | — |
| Operating Margin | -612.0% | -86.5% |
| Net Margin | -576.1% | 75.7% |
| Revenue YoY | 2.2% | — |
| Net Profit YoY | -33.6% | 179.1% |
| EPS (diluted) | $-0.83 | $-3.74 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.6M | $13.7M | ||
| Q3 25 | $7.9M | $19.1M | ||
| Q2 25 | $44.1M | $8.1M | ||
| Q1 25 | $18.5M | $2.9M | ||
| Q4 24 | $13.3M | — | ||
| Q3 24 | $12.6M | — | ||
| Q2 24 | $12.1M | — | ||
| Q1 24 | $16.6M | — |
| Q4 25 | $-78.2M | $10.4M | ||
| Q3 25 | $-86.4M | $-16.3M | ||
| Q2 25 | $-43.5M | $-15.8M | ||
| Q1 25 | $-56.4M | $-13.3M | ||
| Q4 24 | $-58.5M | — | ||
| Q3 24 | $-49.0M | — | ||
| Q2 24 | $-44.5M | — | ||
| Q1 24 | $-41.5M | — |
| Q4 25 | -612.0% | -86.5% | ||
| Q3 25 | -1157.7% | -10.1% | ||
| Q2 25 | -109.7% | -177.7% | ||
| Q1 25 | -340.7% | -472.7% | ||
| Q4 24 | -486.7% | — | ||
| Q3 24 | -433.8% | — | ||
| Q2 24 | -401.4% | — | ||
| Q1 24 | -272.6% | — |
| Q4 25 | -576.1% | 75.7% | ||
| Q3 25 | -1094.8% | -85.4% | ||
| Q2 25 | -98.7% | -196.0% | ||
| Q1 25 | -305.4% | -452.7% | ||
| Q4 24 | -440.7% | — | ||
| Q3 24 | -388.9% | — | ||
| Q2 24 | -368.4% | — | ||
| Q1 24 | -250.3% | — |
| Q4 25 | $-0.83 | $-3.74 | ||
| Q3 25 | $-1.03 | $-0.11 | ||
| Q2 25 | $-0.52 | $-0.16 | ||
| Q1 25 | $-0.67 | $-0.18 | ||
| Q4 24 | $-0.74 | — | ||
| Q3 24 | $-0.67 | — | ||
| Q2 24 | $-0.71 | — | ||
| Q1 24 | $-0.76 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $247.0M | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $538.7M | $35.3M |
| Total Assets | $688.1M | $154.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $247.0M | $137.5M | ||
| Q3 25 | $78.4M | $103.8M | ||
| Q2 25 | $84.3M | $121.6M | ||
| Q1 25 | $75.9M | $89.1M | ||
| Q4 24 | $110.0M | — | ||
| Q3 24 | $99.0M | — | ||
| Q2 24 | $116.8M | — | ||
| Q1 24 | $49.8M | — |
| Q4 25 | $538.7M | $35.3M | ||
| Q3 25 | $372.3M | $-8.1M | ||
| Q2 25 | $447.6M | $7.1M | ||
| Q1 25 | $480.9M | $10.7M | ||
| Q4 24 | $527.0M | — | ||
| Q3 24 | $376.9M | — | ||
| Q2 24 | $370.7M | — | ||
| Q1 24 | $168.7M | — |
| Q4 25 | $688.1M | $154.7M | ||
| Q3 25 | $522.5M | $133.7M | ||
| Q2 25 | $591.6M | $133.8M | ||
| Q1 25 | $615.0M | $103.7M | ||
| Q4 24 | $669.3M | — | ||
| Q3 24 | $513.6M | — | ||
| Q2 24 | $511.0M | — | ||
| Q1 24 | $312.7M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-67.8M | $-2.0M |
| Free Cash FlowOCF − Capex | $-73.0M | $-2.1M |
| FCF MarginFCF / Revenue | -537.4% | -15.3% |
| Capex IntensityCapex / Revenue | 37.8% | 0.7% |
| Cash ConversionOCF / Net Profit | — | -0.19× |
| TTM Free Cash FlowTrailing 4 quarters | $-263.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-67.8M | $-2.0M | ||
| Q3 25 | $-57.4M | $-17.5M | ||
| Q2 25 | $-63.2M | $-14.5M | ||
| Q1 25 | $-61.1M | $29.0M | ||
| Q4 24 | $-48.8M | — | ||
| Q3 24 | $-42.2M | — | ||
| Q2 24 | $-39.7M | — | ||
| Q1 24 | $-42.0M | — |
| Q4 25 | $-73.0M | $-2.1M | ||
| Q3 25 | $-60.1M | — | ||
| Q2 25 | $-65.8M | $-14.9M | ||
| Q1 25 | $-64.6M | $29.0M | ||
| Q4 24 | $-50.9M | — | ||
| Q3 24 | $-44.5M | — | ||
| Q2 24 | $-41.6M | — | ||
| Q1 24 | $-44.8M | — |
| Q4 25 | -537.4% | -15.3% | ||
| Q3 25 | -761.3% | — | ||
| Q2 25 | -149.4% | -184.0% | ||
| Q1 25 | -349.9% | 988.3% | ||
| Q4 24 | -382.8% | — | ||
| Q3 24 | -353.7% | — | ||
| Q2 24 | -344.4% | — | ||
| Q1 24 | -270.3% | — |
| Q4 25 | 37.8% | 0.7% | ||
| Q3 25 | 34.3% | 0.0% | ||
| Q2 25 | 6.1% | 5.0% | ||
| Q1 25 | 18.9% | 0.8% | ||
| Q4 24 | 15.8% | — | ||
| Q3 24 | 18.6% | — | ||
| Q2 24 | 16.0% | — | ||
| Q1 24 | 17.4% | — |
| Q4 25 | — | -0.19× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NRIX
| Pfizer | $11.9M | 88% |
| Gilead Agreement | $1.7M | 13% |
XLO
Segment breakdown not available.
